Zobrazeno 1 - 10
of 259
pro vyhledávání: '"giant cell tumour of bone"'
Autor:
Raja Amri, Ameni Chelly, Mariem Ayedi, Mohammed A. Rebaii, Sami Aifa, Sabeur Masmoudi, Hassib Keskes
Publikováno v:
Bone & Joint Research, Vol 13, Iss 2, Pp 84-91 (2024)
Aims: The present study investigated receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), and Runt-related transcription factor 2 (RUNX2) gene expressions in giant cell tumour of bone (GCTB) patients in relationship wi
Externí odkaz:
https://doaj.org/article/9f8199cb506c4ffc89ff2234f94d7888
Publikováno v:
Journal of Bone Oncology, Vol 45, Iss , Pp 100596- (2024)
A 31-year-old woman was diagnosed with a recurrent and rapidly growing giant cell tumour of distal tibia with skin ulceration after intralesional curettage. The patient started on Denosumab 120 mg subcutaneously, once per month with additional loadin
Externí odkaz:
https://doaj.org/article/fc87ccb4fbc74e71a59d236186ae79b1
Publikováno v:
EFORT Open Reviews, Vol 8, Iss 12, Pp 895-905 (2023)
Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denos
Externí odkaz:
https://doaj.org/article/1828996cd5ad46c8bb8b2be7eea3d916
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lizz van der Heijden, Sjaan Bindt, Maurizio Scorianz, Colin Ng, Max C. L. H. Gibbons, Michiel A. J. van de Sande, Domenico A. Campanacci
Publikováno v:
Bone & Joint Open, Vol 3, Iss 7, Pp 515-528 (2022)
Aims: Giant cell tumour of bone (GCTB) treatment changed since the introduction of denosumab from purely surgical towards a multidisciplinary approach, with recent concerns of higher recurrence rates after denosumab. We evaluated oncological, surgica
Externí odkaz:
https://doaj.org/article/ecae5314a1cc4fc29ef9518aa141d476
Autor:
Signe Sparre Beck-Nielsen, Henrik Hasle, Akmal Safwat, Kestutis Valancius, Bente Langdahl, Ebbe Stender Hansen
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101687- (2023)
A giant cell tumour of bone presented in the os sacrum of a prepubertal girl. Surgery with reconstruction was performed, but total resection was impossible. Zoledronate failed to avoid tumour regrowth, and treatment was changed to denosumab, despite
Externí odkaz:
https://doaj.org/article/ca1a40a5baf04e55bea655437e9fb4f6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1302-1313 (2021)
Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and h
Externí odkaz:
https://doaj.org/article/cd4df86465de415d8724ae05dba35f50
The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone
Publikováno v:
World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-5 (2021)
Abstract Background Denosumab (XgevaTM) is a fully human antibody to RANK-Ligand, an important signal mediator in the pathogenesis of giant cell tumour of bone (GCTB). The use of denosumab in the treatment of GCTB has changed the way in which these t
Externí odkaz:
https://doaj.org/article/4a4b03c377fa45df85eabddac3db6ced